Inhaled steroids associated with decreased macrophage markers in nonasthmatic individuals with sickle cell disease in a randomized trial
Inhaled mometasone was shown to improve pain scores and decrease soluble vascular cell adhesion molecule (sVCAM) concentration in a randomized controlled trial of nonasthmatic patients with sickle cell disease. We sought to explore potential changes in systemic inflammation as a mechanism underlying this effect. Serum samples from 41 trial participants (15 placebo- and 26 mometasone-treated) were analyzed using a 92 inflammatory marker panel at baseline and after 8 weeks of mometasone therapy. Individual marker analysis and correlation analysis were conducted. Adjusted for age, the mometasone-treated group decreased the concentration of CXCL9, CXCL11, CD40, IL-10, and IL-18 relative to placebo-treated participants. Hierarchical clustering and correlation analysis identified additional evidence for a decrease in cytokines linking to macrophage signaling and migration. There was no statistically significant change in markers of asthma and allergy, indicating that the improvement was unlikely mediated by modulation of occult reactive airway disease. This analysis of inflammatory markers suggests that decrease in macrophage activity may be involved in the mediation of the clinical benefit seen with use of inhaled mometasone in nonasthmatic patients with sickle cell disease.
Trial registration: clinicaltrials.gov identifier: NCT02061202.
KeywordsSickle cell disease Macrophage activation Hemoglobinopathies Inhaled corticosteroids
The authors would like to thank Jason Connor and Wil Meurer for Bayesian statistical support and Alexa Punzalan for trial oversight and execution.
This study was funded by the National Heart, Lung and Blood Institute (IND #117997).
Compliance with ethical standards
Conflict of interest
The authors declare they have no conflicts of interest.
All procedures performed in this study were in accordance with the ethical standards of the institutional review board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individuals included in the study.
- 2.Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W (1989) Mortality in children and adolescents with sickle cell disease. Cooperative study of sickle cell disease. Pediatrics 84(3):500–508Google Scholar
- 3.Nandedkar SD, Feroah TR, Hutchins W, Weihrauch D, Konduri KS, Wang J, Strunk RC, DeBaun MR, Hillery CA, Pritchard KA (2008) Histopathology of experimentally induced asthma in a murine model of sickle cell disease. Blood 112(6):2529–2538. https://doi.org/10.1182/blood-2008-01-132506 CrossRefGoogle Scholar
- 4.Pritchard KA Jr, Feroah TR, Nandedkar SD, Holzhauer SL, Hutchins W, Schulte ML, Strunk RC, Debaun MR, Hillery CA (2012) Effects of experimental asthma on inflammation and lung mechanics in sickle cell mice. Am J Respir Cell Mol Biol 46(3):389–396. https://doi.org/10.1165/rcmb.2011-0097OC CrossRefGoogle Scholar
- 8.Torres LS, Okumura JV, Silva DG, Mimura KK, Belini-Junior E, Oliveira RG, Lobo CL, Oliani SM, Bonini-Domingos CR (2016) Inflammation in sickle cell disease: differential and down-expressed plasma levels of annexin A1 protein. PLoS One 11(11):e0165833. https://doi.org/10.1371/journal.pone.0165833 CrossRefGoogle Scholar
- 11.Shiu YT, Udden MM, McIntire LV (2000) Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. Blood 95(10):3232–3241Google Scholar
- 12.Setty BN, Stuart MJ (1996) Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. Blood 88(6):2311–2320Google Scholar
- 16.Vinchi F, Costa da Silva M, Ingoglia G, Petrillo S, Brinkman N, Zuercher A, Cerwenka A, Tolosano E, Muckenthaler MU (2016) Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease. Blood 127(4):473–486. https://doi.org/10.1182/blood-2015-08-663245 CrossRefGoogle Scholar
- 18.Dasgupta SK, Thiagarajan P (2005) The role of lactadherin in the phagocytosis of phosphatidylserine-expressing sickle red blood cells by macrophages. Haematologica 90(9):1267–1268Google Scholar
- 19.Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM (2000) Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood 96(7):2451–2459Google Scholar
- 25.Chana KK, Fenwick PS, Nicholson AG, Barnes PJ, Donnelly LE (2014) Identification of a distinct glucocorticosteroid-insensitive pulmonary macrophage phenotype in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 133(1):207–216 e201–211. https://doi.org/10.1016/j.jaci.2013.08.044 CrossRefGoogle Scholar
- 27.Cai Y, Sugimoto C, Arainga M, Alvarez X, Didier ES, Kuroda MJ (2014) In vivo characterization of alveolar and interstitial lung macrophages in rhesus macaques: implications for understanding lung disease in humans. J Immunol 192(6):2821–2829. https://doi.org/10.4049/jimmunol.1302269 CrossRefGoogle Scholar
- 29.Petrov VP (1966) Complications of sickle-cell anemia. Klin Med (Mosk) 44(1):94–98Google Scholar
- 33.Galadanci NA, Liang WH, Galadanci AA, Aliyu MH, Jibir BW, Karaye IM, Inusa BP, Vermund SH, Strunk RC, DeBaun MR (2015) Wheezing is common in children with sickle cell disease when compared with controls. J Pediatr Hematol Oncol 37(1):16–19. https://doi.org/10.1097/MPH.0000000000000239 CrossRefGoogle Scholar
- 36.Glassberg J, Spivey JF, Strunk R, Boslaugh S, DeBaun MR (2006) Painful episodes in children with sickle cell disease and asthma are temporally associated with respiratory symptoms. J Pediatr Hematol Oncol 28(8):481–485. https://doi.org/10.1097/01.mph.0000212968.98501.2b CrossRefGoogle Scholar
- 40.Glassberg J, Minnitti C, Cromwell C, Cytryn L, Kraus T, Skloot GS, Connor JT, Rahman AH, Meurer WJ (2017) Inhaled steroids reduce pain and sVCAM levels in individuals with sickle cell disease: a triple-blind, randomized trial. Am J Hematol 92(7):622–631. https://doi.org/10.1002/ajh.24742 CrossRefGoogle Scholar
- 42.Niu X, Nouraie M, Campbell A, Rana S, Minniti CP, Sable C, Darbari D, Dham N, Reading NS, Prchal JT, Kato GJ, Gladwin MT, Castro OL, Gordeuk VR (2009) Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease. PLoS One 4(11):e7956. https://doi.org/10.1371/journal.pone.0007956 CrossRefGoogle Scholar
- 43.Sarray S, Saleh LR, Lisa Saldanha F, Al-Habboubi HH, Mahdi N, Almawi WY (2015) Serum IL-6, IL-10, and TNFalpha levels in pediatric sickle cell disease patients during vasoocclusive crisis and steady state condition. Cytokine 72(1):43–47. https://doi.org/10.1016/j.cyto.2014.11.030 CrossRefGoogle Scholar
- 44.Lanaro C, Franco-Penteado CF, Albuqueque DM, Saad ST, Conran N, Costa FF (2009) Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy. J Leukoc Biol 85(2):235–242. https://doi.org/10.1189/jlb.0708445 CrossRefGoogle Scholar